(MedPage Today) — Phase II results called “encouraging” though most endpoints missed.
Uncategorized
Sight Again project receives €18.5 million in funding
GenSight Biologics, Pixium Vision and Fondation Voir et Entendre announced that the Sight Again project will receive €18.5 million in funding over the next 5 years as part of the Investment for the Future, according to a press release.Sight Again is a public-private research and development project to restore vision to legally blind patients with different stages of retinitis pigmentosa. Sight Again is focused on the development of two products: an optogenetic gene therapy product (GenSight Biologics) and a vision restoration system with Prima, a retinal implant (Pixium Vision), the (Read more...)
Uncategorized
VIDEO: Three pearls for cataract surgery in glaucoma patients, part 2
NEW YORK – Robert Noecker, MD, MBA, discusses how surgeons can use cataract surgery to achieve good refractive outcomes in glaucoma patients.
Uncategorized
What are the advantages/disadvantages of having the same surgeon perform both the femto and phaco portions of cataract surgery?
Patients are usually most aware of who is doing the laser portion of the cataract procedure because he or she is less sedated and wears no drape to cover the other eye. It is the more frightening part of the procedure. Having a single surgeon perform all aspects of the procedure is the cleanest way to proceed because the patient has a bond with one surgeon and has little question as to who actually did the surgery.From a patient’s perspective, it is all a part of the same procedure. Patients (Read more...)
Uncategorized
Glaucoma trials affect clinical practice in varying ways
Interpretation of trial results factors into the impact of randomized clinical trials on glaucoma practice, according to a survey.The electronic survey was sent to members of the American Glaucoma Society, and a 5-point Likert scale was used to rate re…
Iluvien Update 9: Additional Marketing Approvals; A New Ophthalmic Application; and An Interesting Human Interest Story
Since I last wrote about Iluvien back in September (Iluvien Update 8: Alimera Sciences Receives FDA Approval of Iluvien for Treatment of DME), when Alimera Sciences and pSivida announced the FDA approval of Iluvien for treating chronic DME, adding the U.S. to the approvals or pending approvals obtained in seventeen European countries – approved in thirteen and pending approval in an additional four others, the product has become commercially available in the UK and Germany and is scheduled to become available in Portugal shortly.
With the FDA approval, Iluvien should also become commercially available in the U.S. in (Read more...)